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About 150 participants from 16 countries gathered at 
the above meeting organized by the Central Institute of 
Molecular Biology of the Academy of Sciences of the 
GDR, sponsored by the Biochemische Gesellschaft der 
DDR and Shimadzu Corporation (Europe) and held 
under the patronage of UNESCO. UNESCO support 
enabled the attendance of several participants from 
developing countries. 
One major objective of the meeting was to discuss 
growth inhibitory factors in conjunction with growth 
stimulating factors. 
Reviews of the current knowledge on the multifunc- 
tional transforming growth factor (TGF-beta) 
(Bascom, Nashville Thorgeirsson, Bethesda; Stoika, 
Lvov) clearly indicated the relevance of its growth in- 
hibitory activity observed in vitro for several 
physiological and pathological situations in vivo. In 
liver, the growth inhibitory action of TGF-beta 1 seems 
to be linked to the induction of differentiation. Normal 
rat liver cells, transformed by a variety of methods lose 
their responsiveness to TGF-beta, suggesting that such 
a lost growth control could be involved in 
tumorigenesis (Thorgeirsson, Bethesda). 
Interferons, another group of polypeptide growth in- 
hibitors,(reviewed by Inglot, Warsaw) exert their 
growth inhibitory action, at least in some cell systems, 
by mechanisms distant from the antiviral response 
(Clemens et al., London). 
Inhibitors of hematopoetic stem cell proliferation as 
the ‘hemoregulatory peptide’ (a synthetic pentapeptide 
reviewed by Laerum, Bergen) attract special medical in- 
terest because of a potential bone marrow protection in 
anti-proliferative tumor chemotherapy. The potent 
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growth promoting effects of disulfide-linked dimers of 
the same peptide suggest he possibility of another level 
of regulation in terms of monomer-dimer conversions 
which might be of relevance also in connection with 
other factor-controlled systems. A synergism of the 
dimeric ‘hemoregulatory peptide’ as well as of several 
nucleosides with CSF in stimulating bone marrow stem 
cell proliferation might also be of medical interest for 
the management of leucopenia (Langen, Berlin). 
Whereas Glaeser et al. (Halle) were able to identify 
an ‘inhibitor’ of the ‘cell-flattening effect’ required for 
the initiation of DNA synthesis in lens epithelial cells as 
a combined action of adenine and inorganic phosphate, 
the identity of the ‘epidermal Gl chalone’ is not yet 
clear, although extremely active preparations (active at 
1 pg/ml) are available. However, the factor is by 
several criteria clearly distinct from TGF-beta (Richter, 
Heidelberg). 
‘Mammary-derived growth inhibitor’ (MDGI), a 
14.5 kDa polypeptide with growth inhibitory activity 
for a variety of mammary epithelial cells (Grosse, 
Berlin), was shown to have inhibitory effects on fi- 
adrenergic responses in neonatal rat heart myocytes, 
suggesting an involvement of this signaling pathway 
also in the growth inhibitory action (Wallukat, Berlin). 
A previously shown lipid-bindig activity of MDGI 
could be dissociated from its anti-,f3-adrenergic effect by 
employing synthetic MDGI peptides, which do not bind 
hydrophobic ligands (Boehmer, Berlin). 
The enormous complexity which emerged in the last 
few years in the diverse effects of various factors on cell 
growth may not only be due to the various interactions 
of different growth factors and growth inhibitors but 
might also in part be related to a complex diversity at 
the level of the receptors for one and the same growth 
effector. The A-type platelet-derived growth factor 
(PDGF) receptor can bind all known isoforms of 
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PDGF (i.e. AA and BB homodimers, as well as AB 
heterodimers) whereas the B-type PDGF receptor can 
bind only BB homodimers with high affinity (Heldin, 
Uppsala). Since only BB homodim~rs can elicit actin 
reorganization and membrane ruffling in target cells, a 
differential signaling of both receptor types has to be 
assumed. Functional receptors most likely consist of 
dimers formed by association of either homologous or 
heterologous receptor monomers under the influence of 
the ligand. The shift of the receptor dimerization 
equilibrium upon ligand binding can then lead to an an- 
tagonistic action of one ligand with respect to the ac- 
tion of another one. This was demonstrated for the 
actin reorganization response elicited by PDGF-BB. In 
cells pretreated with PDGF-AA to down-regulate the 
A-type receptor, PDGF-AB behaves as an antagonist 
for PDGF-BB. The explanation is that PDGF-AB will 
occupy B-type receptors without the formation of func- 
tional receptor dimers due to the absence of A-type 
receptors. 
In the case of the TGF-beta family, it will be in- 
teresting to see whether greater diversity at the receptor 
level as currently known can explain the strikingly dif- 
ferent effects of the TGF isoforms l-3 on the level of 
the different TGF-beta mRNAs (Bascom, Nashville). 
At the moment, the three TGF-beta species available as 
purified proteins seem to be largely cross-reactive with 
respect to interactions with the same set of three dif- 
ferent membrane receptors, identified on the basis of 
affinity cross-linking. 
The important field of the relevance of growth fac- 
tors for the cardiovascular system was addressed by on- 
ly a few contributors. The data of Sharma (Bad 
Nauheim) on increased expression of TGF-beta and 
beta-ECGF (endothelial cell growth factor, a member 
of the fibroblast growth factor (FGF) family) in an ex- 
perimental ischemia model, clearly indicating the 
relevance of these factors in neov~cularization in the 
heart, were quite interesting. 
Comparatively, many contributions were devoted to 
the problem of the involvement of specific growth fac- 
tors or their receptors in malignant proliferation of 
transformed cells and the possible usefulness of respec- 
tive data in the diagnosis and treatment of tumor pa- 
tients. 
Truncations of growth factor receptors of the protein 
tyrosine kinase type are involved in the subversion of 
normal receptor function by various oncogenes. Res- 
pective receptor defects can be mimicked with suitable 
genetic constructs derived from the wild-type epidermal 
growth factor (EGF) receptor c-DNA and transfected 
into recipient cells (Panayotou, London). In the 
presence of EGF, overexpression of the wild-type 
receptor also results in a transformed phenotype. 
A high expression of TGF-alpha has been linked with 
the transformed phenotype in NOG8 mouse mammary 
epithelial cells transformed by either the ras oncogene 
158 
(under a dexamethasone-inducible promotor) or neu 
(Salomon, Bethesda). However, TGF-alpha seems to 
be a relatively poor mitogen, at least for MCF? human 
mammary c~cinoma cells (Van Zoelen, N~egen). 
This led to the suggestion that at least some of the 
growth factors expressed in mammary tumors (i.e. 
TGF-alpha and PDGF) might affect the surrounding 
stroma rather than acting in an autocrine manner (Van 
Zoelen). 
How these in vitro data relate to the in vivo situation 
is not clear. The EGF receptor status of human mam- 
mary carcinomas is inversely correlated with the 
estrogen receptor status (Smith, London; Perez, 
Havana) and the expression of the EGF receptor has 
been demonstrated as being of prognostic significance 
for the outcome of the disease (Perez). Of similar value 
is the estimation of the expression of c-erbB2 coding 
for a growth factor receptor with unknown ligand (the 
human variant of the rat neu oncogene) (Hynes, Basel). 
With data for both growth factor receptors, estrogen 
receptor (ER) data can be stratified to identify pa- 
tient groups (ER + and EGF-R- or ER + and c- 
erbB2 - with clearly better prognosis. Whereas the 
receptor coded by c-erbB2 can obviously undergo 
cross-activation by the EGF receptor (another example 
of receptor heterodimer formation?) (Hynes), TGF- 
alpha is currently believed to be the physiologic~ly 
relevant ligand for the EGF receptor either as a soluble 
molecule or (as speculated by Bauknecht, Freiburg) in 
the form of its membrane located precursor, 
demonstrated to act on neighboring cells in vitro 
(Petrides, Munich). Or are high-molecular-mass forms 
of EGF of relevance for stimulating m~mary tumor 
growth? K. Eckert (Berlin) identified a 43 kDa EGF- 
like protein in the urine of breast cancer patients and 
showed its activity to be correlated with typical pro- 
gnostic breast cancer markers. Further data are re- 
quired however, to establish the relevance of an 
‘autocrine loop’ used by the mammary carcinoma cells 
to escape normal growth control. 
A correlation of the expression of TGF-alpha and the 
EGF receptor could be found in human renal car- 
cinoma (Petrides, Munich) and several gynecological 
tumors (Bauknecht, Freiburg). A better response in 
chemotherapy of EGF receptor-positive ovarian car- 
cinomas, however, did not result in improved overall 
survival rates in these patients (Bauknecht). 
Basic FGF might be linked to human brain tumors, 
in particular glioblastomas, where high levels of expres- 
sion could be found in I1 out of 12 cases (Paulus, Vien- 
na). Tissue necrosis was discussed as a possible 
mechanism for this growth factor which is normally not 
secreted to become released. Whether cell damage is a 
general way for a number of growth regulators lacking 
precursors with hydrophobic signal sequences (also 
PD-ECGF, Heldin, Uppsala and MDGI, Grosse, 
Berlin) to reach surface receptors on other cells or 
whether the &phys~~~og~~al iigands” of the eorre- 
spo~d~~g receptors need yet to be discovered, is not 
hIOWn. 
Compaed %o the estab~js~~d bormonaf t~~~~~y of 
Plum&n growth deficiencies with grow& hormone 
fHGH) under mo~~torjng of the ~r~n~ip~ medj~t5r 
~~s~~~n-~ike growth factor-f (IGFI) (Messe, Berlin) or 
wound heating experiments with various growth fac- 
tors, for instance TGF-beta @ascorn, ~a~~~I~e~~ at- 
temps to USIZ growth factors f5r cancer tr~~~rn~t are 
still reiativeiy rare. Page (Stir&e-Fey, Quebec) used 
tra~s~err~n with su~~ss as a vehicle to target 
da~~or~b~~~din to ex~e~me~t~ i~traper~tone~ tumrrrs, 
The report of Perez et al. (Wavannaf on a cIinicaI triag 
with f6 skin czmcer patients treated with hi& doses of 
httman r~~~b~a~t EGF EtppIied in an &amen% w~fs 
quite interesting, A striking remission in a number of 
cases was j~ter~ret~d as a growth inhibition of EGF 
rejector-rich celfs, hawever, a wound healing effect 
could not be ruled out_ 
~ole~~~~ ~~h~isms ~~~~~~ed in rnet~~~~~s might 
be even more promising targets for tumar therapy in 
the future. In addition to ceil-adhesion molecules which 
seem to become lost in transformed celfs, the r~e~~~y 
diseavered ‘scatter’ factors might present positive 
signds for spread@ cells in the body (Birchmeier, 
Es%Xl). 
Regulation of normai grourth and d~ffer~~t~at~o~ in 
the ~~rnrna~ gland w~srzts another important opic of the 
conference. An nt model to study some aspects of 
mam~~ary gland d~fferent~atjo~ in monolayer culture 
use NCIt mouse mammary epithefial c& (Wynes, 
Basel). On& &Is grown in the presemze of EGF res- 
pond afterwards to lactogenic hormones with beta- 
caseia expression. Hctwever, EGF must not be present 
d~r~~~ the Iaetogerdc stimulation, other~se beta-case~~ 
expression is suppressed. 
MDG4f is expressed in B tightly d~ff~~e~t~at~o~- 
coupled fa~~~~~ (Grosse, KWZZ, Berlin] in tke bovine 
mammary gland as demonstrated by an in situ hybridi- 
zation analysis. This promted invest~~at~o~ of the 
possible differ~t~atio~-~ndu~~~g effects of MDGT- 
derived s~thet~~ peptides with promising results ob- 
ttined in a !om-term perf~~~~~ culture of mammary 
gland explants, The latter cuiture system (Binas, Berlin) 
will dlow one to study growth factors under welf- 
defined media ~o~d~~~o~s cl se to in ~~~5 conditions, 
with regard to tissue ~~mpIex~t~ in the future. 
~~tra~e~I~~ar events involved in si~na1~~~ nsf the 
growth factor action were addressed by a finat group of 
contributors. Initiation factors seem to be the mole- 
cular target in protein biosynthesis, where intracellular 
CaZf IeveIs can exert a reg~Iatory function (Panniers, 
Rochester), Fb~sphotyr~si~e pbosphatases in close 
~~5~im~ty to growth factor receptor tyrosine kinases 
might present an effective mews of ~o~~ter-r~~~~atio~ 
for growth factor signaling (Panayatou, London), 
Re~y~I~~~ of EGF-EGF receptor compkxes {up to ~~~~ 
of the receptor in A431 cells) and the existence of func- 
tionaf (in terms of tyrosine kinase aetivityf internalized 
EGF-EGF re~~~t~r complexes were demo~tr~~~ by
Nikdsky et al, ~~e~~~~r~d~. Are thelatter of relevance 
for the growth ~rornot~~~ effect? 
Many genes have bees hitherto put in a sequence at 
least with respect to their time of expression around the 
cell cycle, among them numerous cellufar homologs of 
vi& o~~oge~e~~ A numba aF new genes or proteins 
found to be correlated with a growth response, i.e* an 
extremely ~yciohex~m~~e-sensjt~ve (ceil cyde restrig- 
ting?f ~r~te~~ and a series of genes turned on in late G1 
(Pardee, Boston) and proteins electively expressed in
ex~o~e~t~a~ growth or the statj~~~ phase of Ebrlicb 
.zlscites tumor cellb (p23 arrd ~25, respectiveIy, Biefka e$ 
al., Berlin) needi further investigation toelucidate the& 
place ia the puzzle of j~~~a~el~~~ events of growth fac- 
tor s~~~aI~~g= A specific quenching of these genes by 
antisease nuefeic acids as demanstrated for&~ (Uckert 
et al., Berlin) QT c-fas (VJasscrv et ai,, ~ov~s~b~rsk* 
Moscov, Be&n>; might be the mast stra~~t-forward ap
proach for that. 
